Biomarkers for evaluation of clinical outcomes of hemodiafiltration

Blood Purif. 2013:35 Suppl 1:64-8. doi: 10.1159/000346364. Epub 2013 Feb 25.

Abstract

β2-Microglobulin (β2-MG) is the substance that causes dialysis amyloidosis, and its predialysis value is useful for evaluating the quality of dialysis therapy itself. In addition, β2-MG is also an important biomarker for evaluating the removal performance of hemodialysis and hemodiafiltration (HDF). However, since β2-MG has a molecular weight of 11.8 kDa and can be efficiently removed by diffusion with existing high-performance dialyzers, a higher molecular weight substance should be used for evaluating removal performance of HDF, in which diffusion and convection are performed simultaneously. α1-Microglobulin (α1-MG) has a molecular weight of 33 kDa, and it is removed by convection during dialysis. When we used α1-MG to evaluate the removal performance of HDF in a study based on our own cases, we were able to describe the distinctive features and benefits of HDF with precision. α1-MG removal rate exactly paralleled the changes in symptoms. Kt/V and the β2-MG removal rate, however, did not undergo significant changes as the symptoms fluctuated. α1-MG should be used as a biomarker for evaluation of clinical outcomes of HDF.

Publication types

  • Review

MeSH terms

  • Alpha-Globulins / chemistry
  • Alpha-Globulins / metabolism
  • Biomarkers / blood*
  • Convection
  • Hemodiafiltration* / adverse effects
  • Hemodiafiltration* / methods
  • Humans
  • Prolactin / blood
  • Serum Albumin / metabolism
  • Treatment Outcome
  • beta 2-Microglobulin / blood

Substances

  • Alpha-Globulins
  • Biomarkers
  • Serum Albumin
  • alpha-1-microglobulin
  • beta 2-Microglobulin
  • Prolactin